well-established clinical and Nuclear Medicine recommendations
Effective Dose
19.0 µSv/MBq
Bibliographic Reference
Fassnacht, M., et al. Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment a...
read more
Fassnacht, M., et al. Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020; https://doi.org/10.1016/j.annonc.2020.08.460
read less
Clinical Evaluation
Metabolic activity
Type of Imaging
PET
Grade of Recommendation
B (generally recommended)
Level of Evidence
well-established clinical and Nuclear Medicine recommendations
Effective Dose
19.0 µSv/MBq
Bibliographic Reference
Fassnacht, M., et al. Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment a...
read more
Fassnacht, M., et al. Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020; https://doi.org/10.1016/j.annonc.2020.08.460
read less
Grade of Recommendation
The grade of recommendation relates to the level of evidence on which the recommendation is
based and to the clinical importance of the recommendation (best practice based on the
clinical experience of the referral guideline task force).
A (Strongly recommended)
High level of proof, the recommended nuclear medicine procedure is considered
as a reference imaging procedure for the given indication.
B (generally recommended)
Moderate level of proof, weight of evidence is in favour of usefulness of the nuclear medicine
procedure. The nuclear medicine procedure could be recommended for the
given clinical condition or disease.
C/D (optional)
Low level of proof, the nuclear medicine procedure may can be proposed for establishing the diagnosis
or guiding the therapeutic approach in specific cases for the given clinical condition or disease.
Effective dose
Effective doses related to the injection of the radiopharmaceutical (µSv/MBq). Information
on the recommended injected activities can be found in the corresponding chapter of the
European Nuclear Medicine Guide.
